Pink noise at night may boost memory in early Alzheimer's
NCT ID NCT04570761
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested whether playing a gentle sound called 'pink noise' during deep sleep could strengthen memory in people with early Alzheimer's disease. Nineteen participants wore a special headband that delivered the noise on some nights and not on others. The goal was to see if the noise helped them recall word pairs better the next morning.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pink noise delivered via a Dreem headband
- What this could lead to
- If it works, this could point toward a simple, non-invasive way to help people with Alzheimer's remember better by improving sleep-related memory consolidation.
- What could go wrong
- This is a very small, early proof-of-concept study with only 19 participants. The results may not apply to everyone, and the effect on memory might be small or not last long.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE(AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital of Tours
Tours, 37044, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Zapping the brain to boost memory and mood in Alzheimer's
- Tailored sound waves may sharpen the mind
- Blood test could revolutionize Alzheimer's diagnosis, reducing need for spinal taps and scans
- Blood test could revolutionize Alzheimer's diagnosis at your Doctor's office
- Simple blood test could spot Alzheimer's before symptoms worsen
- New Alzheimer's drug 8M2D enters first human safety trials